BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9846966)

  • 1. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.
    Gorgoulis VG; Zacharatos P; Kotsinas A; Liloglou T; Kyroudi A; Veslemes M; Rassidakis A; Halazonetis TD; Field JK; Kittas C
    Am J Pathol; 1998 Dec; 153(6):1749-65. PubMed ID: 9846966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.
    Gorgoulis VG; Koutroumbi EN; Kotsinas A; Zacharatos P; Markopoulos C; Giannikos L; Kyriakou V; Voulgaris Z; Gogas I; Kittas C
    Mol Med; 1998 Dec; 4(12):807-22. PubMed ID: 9990866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
    Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C
    Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
    Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Liloglou T; Vogiatzi T; Foukas P; Rassidakis G; Garinis G; Ioannides T; Zoumpourlis V; Bramis J; Michail PO; Asimacopoulos PJ; Field JK; Kittas C
    Mol Med; 2000 Mar; 6(3):208-37. PubMed ID: 10965496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
    Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD
    Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical inactivation of p14ARF concomitant with MDM2 overexpression inversely correlates with p53 overexpression in oral squamous cell carcinoma.
    Sano T; Hikino T; Xue Q; Saito T; Kashiwabara K; Oyama T; Nakajima T
    Pathol Int; 2000 Sep; 50(9):709-16. PubMed ID: 11012984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.
    Eymin B; Gazzeri S; Brambilla C; Brambilla E
    Oncogene; 2002 Apr; 21(17):2750-61. PubMed ID: 11965548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of lung.
    Xue Q; Sano T; Kashiwabara K; Oyama T; Nakajima T
    Jpn J Cancer Res; 2001 Mar; 92(3):285-92. PubMed ID: 11267938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity.
    Kinoshita I; Dosaka-Akita H; Mishina T; Akie K; Nishi M; Hiroumi H; Hommura F; Kawakami Y
    Cancer Res; 1996 Dec; 56(24):5557-62. PubMed ID: 8971152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer.
    Hsu HS; Wang YC; Tseng RC; Chang JW; Chen JT; Shih CM; Chen CY; Wang YC
    Clin Cancer Res; 2004 Jul; 10(14):4734-41. PubMed ID: 15269146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low levels of p27 in association with deregulated p53-pRb protein status enhance tumor proliferation and chromosomal instability in non-small cell lung carcinomas.
    Tsoli E; Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Kastrinakis NG; Kokotas S; Kanavaros P; Asimacopoulos P; Bramis J; Kletsas D; Papavassiliou AG; Kittas C
    Mol Med; 2001 Jun; 7(6):418-29. PubMed ID: 11474135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung.
    Xue Q; Sano T; Kashiwabara K; Saito M; Oyama T; Nakajima T
    Pathol Int; 2002 Feb; 52(2):103-9. PubMed ID: 11940214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma.
    Obermann EC; Diss TC; Hamoudi RA; Munson P; Wilkins BS; Camozzi ML; Isaacson PG; Du MQ; Dogan A
    J Pathol; 2004 Feb; 202(2):252-62. PubMed ID: 14743509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
    Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
    Le Frère-Belda MA; Gil Diez de Medina S; Daher A; Martin N; Albaud B; Heudes D; Abbou CC; Thiery JP; Zafrani ES; Radvanyi F; Chopin D
    Hum Pathol; 2004 Jul; 35(7):817-24. PubMed ID: 15257544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
    Gazzeri S; Gouyer V; Vour'ch C; Brambilla C; Brambilla E
    Oncogene; 1998 Jan; 16(4):497-504. PubMed ID: 9484839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of CDKN2 (p16) in non-small cell lung cancer.
    de Vos S; Miller CW; Takeuchi S; Gombart AF; Cho SK; Koeffler HP
    Genes Chromosomes Cancer; 1995 Nov; 14(3):164-70. PubMed ID: 8589032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas.
    Gorgoulis VG; Zacharatos P; Mariatos G; Kotsinas A; Bouda M; Kletsas D; Asimacopoulos PJ; Agnantis N; Kittas C; Papavassiliou AG
    J Pathol; 2002 Oct; 198(2):142-56. PubMed ID: 12237873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p16(INK4A) and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: relationship with tumor growth parameters and ploidy status.
    Mariatos G; Gorgoulis VG; Zacharatos P; Kotsinas A; Vogiatzi T; Rassidakis G; Foukas P; Liloglou T; Tiniakos D; Angelou N; Manolis EN; Veslemes M; Field JK; Kittas C
    Int J Cancer; 2000 Mar; 89(2):133-41. PubMed ID: 10754490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.